Research & Innovation
Publications
Treatment of HCC with Lenvatinib or Regorafenib in combination with Cdk5 inhibition – a new promising therapeutic approach to improve the situation of HCC patients
PMU Author
Petra Huber-Cantonati
All Authors
Petra Huber-Cantonati, L. Kraus, M. A. Ardelt, J. Pachmayr
Abstract
We are sorry. The full text is not available.